The research drew on an exceptionally robust data source: the Korean National Health Insurance Service. In 2004 and 2005, 316,542 adults aged 40 and over took part in a national health screening programme during which their haemoglobin concentrations were measured. The researchers then linked these baseline measurements to national health insurance records and tracked whether participants went on to receive a new diagnosis of dementia through to the end of 2019, a follow-up period extending as long as fifteen years. Rather than treating haemoglobin as a continuous variable alone, the team divided the cohort into five equal groups, or quintiles, ranging from the twenty percent of participants with the lowest haemoglobin levels to the twenty percent with the highest. This design allowed them to compare dementia outcomes across the full spectrum of haemoglobin values observed in a general population.

The results revealed a pattern that was striking in its symmetry at the extremes. People in the lowest quintile of haemoglobin had a sixteen percent higher risk of all-cause dementia compared with the group that showed the lowest dementia rate, while those in the highest quintile carried a seven percent higher risk. In other words, both unusually low and unusually high haemoglobin were associated with elevated risk, with the strongest signal coming from the low end of the distribution. The association was not uniform across dementia subtypes, however, and this nuance is one of the study’s most technically interesting features. For Alzheimer’s disease, the increased risk was concentrated almost entirely among participants with the lowest haemoglobin levels, who showed a fourteen percent higher risk than the reference group.

Vascular dementia, the form of the disease caused by reduced blood flow to the brain, told a different and more complicated story. Participants in the lowest haemoglobin quintile had a nineteen percent higher risk of vascular dementia, while those in the highest quintile had an eighteen percent greater risk. Yet the relationship across all five haemoglobin groups did not follow a simple linear or dose-response pattern, suggesting that whatever mechanisms connect high haemoglobin to vascular dementia may operate differently from those connecting low haemoglobin to the disease. The researchers also observed that the association was clearer and more consistent in women than in men, a sex difference that may reflect biological factors such as iron stores, menstrual blood loss, hormonal influences on erythropoiesis, or differences in baseline haemoglobin distributions between the sexes, though the study design cannot pin down the precise explanation.

Understanding why haemoglobin might matter for the brain requires a brief return to basic physiology. Haemoglobin is the iron-containing protein packed inside red blood cells, and its job is to bind oxygen in the lungs and release it to tissues throughout the body, including the brain. The brain is extraordinarily metabolically demanding, consuming roughly a fifth of the body’s oxygen supply, so any sustained compromise in oxygen-carrying capacity is a plausible threat to neural health. Low haemoglobin is the laboratory hallmark of anaemia, a condition with many possible causes including iron deficiency, chronic disease, kidney dysfunction and nutritional gaps. Chronically reduced oxygen delivery to brain tissue has been implicated in white matter damage, cognitive decline and cerebrovascular injury in previous research, providing a biologically coherent pathway linking anaemia to dementia risk.

High haemoglobin, by contrast, is often a marker of very different processes. Elevated levels can reflect cigarette smoking, dehydration that concentrates the blood, chronic lung or heart disease that triggers compensatory red cell production, or other underlying medical conditions. Some of these factors, particularly smoking and cardiopulmonary disease, are themselves well-established contributors to cerebrovascular damage and dementia. This is why the study’s lead author, Dr Hyun Soo Kim, assistant professor at Dong-A University College of Medicine in Busan, South Korea, is careful to frame haemoglobin as a signal rather than a cause. The findings, he explained, do not show that haemoglobin itself causes dementia, but suggest that abnormal haemoglobin levels may be a visible marker of wider physical vulnerability relevant to brain health.

Dr Kim emphasised the broader context in which the work should be read. Dementia is one of the fastest-growing health challenges in ageing societies, and there are not many treatments and no cure. Identifying simple, accessible markers of future risk could help researchers and clinicians better understand how whole-body health relates to brain health over time. In a statement accompanying the research, he added that a blood test most people already get at a routine check-up may say something about their brain health many years later, noting that in this large Korean cohort people with unusually low haemoglobin, and to a smaller degree those with unusually high haemoglobin, were more likely to develop dementia. He stressed that this does not prove haemoglobin causes dementia, but supports the idea that general physical health, including the body’s ability to carry oxygen, matters for long-term brain health.

Like all observational research, the study comes with important caveats that the authors themselves are careful to spell out. Observational designs can identify associations but cannot prove causation, and reverse causation is a particular concern in dementia research. Early, undiagnosed neurodegenerative processes may begin silently years before any diagnosis is made, and these processes can affect nutrition, frailty, weight loss and appetite in ways that could produce anaemia or otherwise lower haemoglobin. In such a scenario, low haemoglobin would be a consequence of preclinical disease rather than a contributor to it, inflating the apparent association. Confounding by lifestyle factors, socioeconomic status and coexisting illness is also possible, even in a cohort as large as this one, and the Korean population studied may not generalise fully to other ethnic and demographic groups.

Perhaps the most important practical message from the researchers is what the findings do not mean for individual patients. Dr Kim was explicit on this point: the results should not be interpreted as advice to take iron supplements, to raise haemoglobin levels, or to lower high haemoglobin levels in order to prevent dementia. There is no evidence from this study that manipulating haemoglobin would change anyone’s dementia risk, and indiscriminate iron supplementation carries its own health risks. Instead, he advised that an abnormal haemoglobin result should simply be discussed with a doctor, because it may point to underlying health issues that deserve attention in their own right. The value of the finding lies in awareness and follow-up, not in self-treatment.

Independent experts have responded with measured interest. Dr Lindsey Sinclair of the University of Southampton, who was not involved in the work, noted that there is a growing body of evidence that physical health and brain health are intertwined, and that changes supporting better brain health, whether medical or lifestyle changes, are increasingly recognised as important in mid-life to reduce the risk of later dementia. She observed that while the study shows a possible link between haemoglobin levels and dementia risk, more work is required to understand whether this link is present in people from a wider range of backgrounds, and what can best be done to reduce dementia risk in people with the lowest and highest levels of haemoglobin. Her comments capture the consensus view: haemoglobin is a promising and remarkably accessible candidate marker, but it is a starting point for further research rather than a finished clinical tool. For now, the study adds weight to an increasingly persuasive argument that the health of the brain cannot be separated from the health of the body, and that clues about future cognitive decline may already be sitting, unnoticed, in the routine blood results of ordinary check-ups around the world.

Subject of Research: Association between routine haemoglobin blood test levels and long-term dementia risk

Article Title: Routine blood test may suggest future dementia risk

Article References: Routine blood test may suggest future dementia risk. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: dementia, haemoglobin, blood test, Alzheimer's disease, vascular dementia, anaemia, observational study, ECNP Congress, brain health, Korean cohort, risk markers, ageing

The study, published in BMC Medicine by Lanfei Bi, Wenli Li and colleagues working across Nanjing Medical University and several partner institutions, describes a DNA methylation panel measured in peripheral blood that can help distinguish patients with esophageal squamous cell carcinoma from healthy individuals. DNA methylation refers to the addition of methyl groups to cytosine bases, typically at cytosine-guanine dinucleotide sites known as CpG sites. These epigenetic marks regulate gene expression without altering the underlying DNA sequence, and they are among the earliest and most consistent molecular changes that occur during cancer development. Because tumor cells shed DNA into the bloodstream and because immune and blood cell populations themselves respond to malignancy, methylation patterns circulating in blood can serve as a molecular fingerprint of disease occurring elsewhere in the body.

The researchers focused on three genes: HYAL2, which encodes hyaluronan glucosidase 2, an enzyme involved in the breakdown of hyaluronic acid, a component of the extracellular matrix; S100P, a calcium-binding protein implicated in cell proliferation and metastatic behavior; and DYRK4, or dual-specificity tyrosine phosphorylation regulated kinase 4, a signaling kinase. All three have been linked to cancer biology in prior work, but the team’s goal was not simply to confirm their involvement. Instead, they wanted to quantify methylation at specific CpG sites within these genes precisely enough to build a diagnostic classifier, using mass spectrometry to measure methylation levels quantitatively rather than merely detecting the presence or absence of marks.

The study design rested on two independent case-control investigations with a combined total of 601 patients with esophageal squamous cell carcinoma and 802 healthy controls, a sample size that lends considerable statistical weight to the findings. In the first study, the team observed significant hypomethylation, meaning a loss of methyl marks, at 11 of the 16 CpG sites examined across the three genes. The effect was substantial: each 10 percent decrease in methylation was associated with odds ratios ranging from 1.35 to 1.94 for having the disease, with P-values below 0.004. In the second study, which enrolled patients with earlier-stage disease, hypomethylation was confirmed at 9 CpG sites within HYAL2 and S100P, with odds ratios between 1.27 and 1.69 per 10 percent methylation decrease and P-values below 0.001. The replication across two independent cohorts is a critical strength, since many candidate biomarkers fail precisely at this validation stage.

Perhaps the most intriguing biological observation was that methylation differences between cases and controls grew larger in advanced or more aggressive tumors. This dose-response-like relationship suggests that the methylation changes are not random epiphenomena but track with the progression of the malignancy itself. It also raises the possibility that a methylation panel of this kind could eventually carry prognostic information, hinting at tumor stage or aggressiveness before imaging or endoscopy provides that answer. The authors are careful, however, to frame the panel as an auxiliary diagnostic tool, one that would complement rather than replace endoscopic examination and biopsy, which remain the gold standard for confirming esophageal cancer.

To translate the methylation measurements into a practical classifier, the researchers used logistic regression, a statistical method that models the probability of disease as a function of multiple predictor variables while adjusting for covariates such as age and sex. They evaluated performance with receiver operating characteristic curves, summarizing discriminatory ability through the area under the curve, or AUC, a value of 1.0 indicating perfect separation between cases and controls and 0.5 indicating performance no better than chance. In the first study, the methylation panel achieved AUC values between 0.68 and 0.78. In the second study, with earlier-stage cases, the panel reached AUC values of 0.70 to 0.86, a notable result given that early-stage disease is typically the hardest to detect and the most clinically valuable target.

The decisive methodological innovation came when the team incorporated complete blood count parameters into the model. A standard complete blood count measures the proportions and absolute numbers of different circulating cell types, including neutrophils, lymphocytes, monocytes and platelets, and these values are routinely altered in cancer patients through inflammation and immune modulation. When the researchers adjusted the methylation panel of the second study for these hematological parameters, the discriminatory ability improved markedly, yielding AUC values between 0.80 and 0.91 for detecting esophageal squamous cell carcinoma. The logic is elegant: methylation marks capture tumor-derived and tumor-responsive molecular signals, while blood count parameters capture the systemic physiological response to malignancy, and combining the two layers of information produces a classifier stronger than either alone.

The technical pipeline behind the measurements deserves attention as well. Quantitative methylation determination by mass spectrometry, following enzymatic processing steps that included shrimp alkaline phosphatase treatment, offers precision that older qualitative methylation assays lack. The researchers also controlled for potential confounders such as single nucleotide polymorphisms, which can interfere with methylation quantification at nearby CpG sites. Ethics approval was obtained from Nanjing Medical University and the Cancer Hospital of the Chinese Academy of Medical Sciences, and written informed consent was collected from all participants, with the authors declaring no competing interests.

The clinical implications are considerable, particularly for regions where esophageal squamous cell carcinoma is endemic. The disease shows striking geographic clustering, with high-incidence areas in parts of China, Iran and East Africa, where rates can be many times higher than the global average. In such settings, population-wide endoscopic screening is expensive, resource-intensive and uncomfortable for patients, which limits uptake. A blood-based test that could triage individuals for endoscopic follow-up would concentrate invasive procedures on those most likely to benefit. Because the panel relies on quantitative methylation signatures and standard blood count parameters, both of which can be measured in a conventional clinical laboratory, the authors argue that it represents a feasible and efficient strategy for in vitro auxiliary diagnosis.

Cautious interpretation remains essential. Case-control studies demonstrate association and classification performance but do not establish how the panel would perform in a true screening population, where the prevalence of disease is far lower than in a case-control design and false positives carry real costs. Prospective validation in independent cohorts, ideally including patients with premalignant lesions and other esophageal or inflammatory conditions, will be needed to define the panel’s specificity and its place in clinical guidelines. Nevertheless, the study adds to a rapidly growing body of work showing that epigenetic signatures in blood can reveal cancers that are otherwise invisible until late stages. If the findings hold up in larger, population-based trials, a simple blood test reading the methylation patterns of HYAL2, S100P and DYRK4, combined with routine blood count data, could become a powerful ally in catching one of the world’s deadliest cancers while it is still curable.

Subject of Research: A peripheral blood DNA methylation panel for auxiliary diagnosis of esophageal squamous cell carcinoma

Article Title: Peripheral blood-based DNA methylation panel for auxiliary diagnosis of esophageal squamous cell carcinoma

Article References: Bi, L., Li, W., Gu, W., Jin, D., Zhao, Z., Zhao, L., Wu, J., Zhang, J., Song, Y., Jiang, Y., & Yang, R. (2026). Peripheral blood-based DNA methylation panel for auxiliary diagnosis of esophageal squamous cell carcinoma. BMC Medicine. https://doi.org/10.1186/s12916-026-05209-9

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05209-9

Keywords: DNA methylation, esophageal squamous cell carcinoma, epigenetics, biomarkers, HYAL2, S100P, DYRK4, blood test, cancer diagnosis, complete blood count, mass spectrometry, early detection

The logic behind the ratio rests on two well-studied biological threads. GGT is an enzyme found mainly in the liver and biliary tract, and elevated blood levels have long been linked not only to liver disease but also to oxidative stress, inflammation, and metabolic dysfunction. Population studies have repeatedly associated higher GGT with diabetes, high blood pressure, fatty liver disease, and atherosclerosis, the gradual narrowing of arteries that underlies heart attacks. HDL cholesterol, meanwhile, is widely regarded as protective because it participates in reverse cholesterol transport, ferrying cholesterol away from artery walls back to the liver. When GGT is high and HDL is low at the same time, the resulting ratio captures two damaging tendencies in a single number: a burden of oxidative and metabolic stress paired with a weakened defense system. Combining the two into one indicator, researchers hoped, might outperform either measurement alone and offer clinicians a cheap, readily available window into cardiovascular risk.

To test that idea, the team led by Sisi Chen and colleagues at Wuhan Fourth Hospital conducted a retrospective longitudinal cohort study of 3,123 female patients. The women were evaluated for coronary heart disease, and the researchers used multivariable logistic regression to ask whether a higher standardized GHR was independently associated with having the disease, after accounting for a broad range of clinical and laboratory covariates. The answer was a clear yes. Each one-standard-deviation increase in the ratio was associated with roughly two and a half times the odds of coronary heart disease, with a fully adjusted odds ratio of 2.466 and a 95 percent confidence interval of 1.943 to 3.130, a result that remained highly statistically significant. In conventional receiver operating characteristic analysis, the ratio showed modest ability to discriminate between women with and without the disease, achieving an area under the curve of 0.741.

The investigators then turned to the forward-looking question: among women who already had coronary heart disease, did the ratio predict future trouble? During a median follow-up of 665 days, 611 major adverse cardiovascular events occurred in the cohort. In a complete-case Cox regression model that included 683 patients with 183 events, and that was additionally adjusted for low-density lipoprotein cholesterol along with other clinical and laboratory variables, each one-standard-deviation rise in GHR was associated with a 49.8 percent higher rate of major adverse cardiovascular events, corresponding to a hazard ratio of 1.498 with a confidence interval of 1.358 to 1.653. The dose-response pattern was striking. When patients were divided into tertiles, or thirds, by their baseline ratio, women in the middle third had nearly double the event rate of those in the lowest third, with a fully adjusted hazard ratio of 1.902, while those in the highest third had more than three times the rate, at 3.291. The trend across tertiles was highly significant.

These findings place the GHR in a growing family of combined lipid-and-enzyme markers that researchers have proposed as refinements to traditional cholesterol panels. Standard risk assessment relies heavily on low-density lipoprotein cholesterol, total cholesterol, and related measures, yet many women who suffer cardiovascular events do not have dramatically abnormal values on those tests. Coronary heart disease in women has historically been under-recognized and under-studied, and sex-specific risk markers remain an active frontier in cardiology. A ratio assembled from two tests that are already ordered routinely—liver function panels include GGT, and lipid panels include HDL cholesterol—would cost nothing extra to calculate, which is precisely what makes such markers attractive. The Wuhan study’s large female-only cohort and its adjustment for numerous confounders, including lipid-lowering therapy, lend considerable weight to the observed associations.

However, the study’s most instructive finding may be the one that tempers enthusiasm. When the researchers applied a more rigorous, time-dependent form of receiver operating characteristic analysis focused specifically on the first 365 days of follow-up—a method that properly accounts for censoring, meaning patients whose follow-up ends before the full year—the ratio’s discriminative power collapsed. The area under the curve fell to just 0.594 overall, and across age subgroups it ranged only from 0.593 to 0.623, with no statistically significant differences between age groups. This is a stark contrast with the exploratory conventional ROC analysis, which had suggested the best discrimination among patients aged 75 and older, with an area under the curve of 0.737. The discrepancy illustrates a methodological pitfall in biomarker research: conventional ROC analyses that ignore censoring can overstate a marker’s predictive performance, and the authors’ decision to run both analyses side by side provides an unusually honest appraisal.

The authors are explicit about the implication. Higher GHR, they conclude, is associated with coronary heart disease and with the occurrence of major adverse cardiovascular events in women with the disease, but baseline GHR alone shows limited discrimination for one-year events and should not be considered a standalone short-term risk prediction marker. In practical terms, a high ratio may flag a woman as belonging to a higher-risk stratum, but it cannot tell a clinician with confidence whether a specific patient will experience a heart attack, stroke, or cardiovascular death within the next twelve months. The researchers also emphasize that prospective external validation is required before GHR can be incorporated into clinical risk assessment. Because the study was retrospective and conducted at a single institution in China, its findings must be reproduced in independent, diverse populations before any change to practice could be justified.

The study also has structural limitations worth understanding. Retrospective designs rely on data collected for clinical rather than research purposes, which can introduce measurement variability and missing information; the complete-case Cox model included only 683 of the 3,123 enrolled patients, a substantial reduction that may affect precision and generalizability. Residual confounding remains possible even after extensive adjustment, since factors such as diet, physical activity, alcohol consumption, and detailed medication adherence are difficult to capture fully in routine records. The authors note that they examined variance inflation factors to check for multicollinearity among covariates, and their supplementary analyses included correlations between GHR and the Gensini score, a measure of coronary artery disease severity, as well as Kaplan-Meier survival curves stratified by GHR tertiles, which visually confirmed the gradient in event-free survival across risk groups.

What emerges from this research is a nuanced picture rather than a breakthrough headline. The GGT-to-HDL-cholesterol ratio is a genuine and statistically robust signal: it reflects the convergence of oxidative stress and impaired cholesterol handling, it correlates with the presence and severity of coronary disease in women, and it stratifies patients into meaningfully different risk tiers over a follow-up period approaching two years. At the same time, the study demonstrates that association and prediction are not the same thing, and that a biomarker cheap enough to calculate on the back of any lab report still needs to clear a high bar before it can guide individual decisions. For now, the ratio is best viewed as a promising adjunct—a number that may enrich risk conversations between women and their cardiologists—while the search for reliable, sex-specific short-term predictors continues. The full open-access study is available with the DOI 10.1186/s12902-026-02534-1.

Subject of Research: The GGT-to-HDL-cholesterol ratio as a biomarker for coronary heart disease and cardiovascular outcomes in women

Article Title: Association between the gamma-glutamyl transferase to high-density-lipoprotein-cholesterol ratio and clinical outcomes in female patients with coronary heart disease

Article References: Association between the gamma-glutamyl transferase to high-density-lipoprotein-cholesterol ratio and clinical outcomes in female patients with coronary heart disease. (n.d.). https://doi.org/10.1186/s12902-026-02534-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02534-1

Keywords: GGT-to-HDL ratio, coronary heart disease, women's health, biomarkers, cardiovascular risk, major adverse cardiovascular events, HDL cholesterol, gamma-glutamyl transferase, Cox regression, risk prediction, BMC Endocrine Disorders, retrospective cohort study

Sepsis is a catastrophic dysregulation of the body’s response to infection, and it remains one of the leading causes of death worldwide, yet confirming it as the actual cause of death after a person has died is notoriously difficult. Autopsy findings in sepsis are often nonspecific: congestion, edema, and inflammatory infiltrates can be seen in many conditions, and the organs of a person who died of sepsis may look deceptively normal, particularly if death came quickly. Postmortem microbiology is similarly treacherous, because bacteria begin colonizing the body within hours of death, a process known thanatomicrobiologists call postmortem bacterial translocation. Cultures taken from a corpse can therefore grow organisms that had nothing to do with the fatal illness. Forensic pathologists have consequently searched for decades for a biochemical signature that survives death and still tells the truth about what killed the person.

Procalcitonin emerged as a candidate because of its unusual biology. In healthy people, procalcitonin is produced almost exclusively by the C cells of the thyroid gland as a precursor of the hormone calcitonin, and circulating levels remain vanishingly low. During systemic bacterial infection, however, extra-thyroidal tissues throughout the body, including liver, lung, kidney, adipose tissue, and muscle, are induced to express the CALC-1 gene, and procalcitonin levels can climb by several orders of magnitude within a few hours. The molecule is not substantially degraded after death, and previous forensic studies have shown that it remains measurable and relatively stable across extended postmortem intervals. That stability is precisely what makes it attractive as a postmortem marker, since bodies do not always arrive at the morgue promptly and decomposition begins immediately.

The new analysis, led by Aswini Chandran and colleagues, was rigorous in its design. The team searched four major databases, PubMed, Scopus, ScienceDirect, and the Cochrane Library, for studies that evaluated procalcitonin levels in postmortem samples. Eleven studies met the inclusion criteria, and eight of them provided sufficient data for pooled statistical analysis. Rather than relying on simple pooling alone, the researchers applied two sophisticated models designed specifically for diagnostic accuracy synthesis: the Reitsma bivariate random-effects model and the hierarchical summary receiver operating characteristic, or HSROC, analysis. These methods account for the trade-off between sensitivity and specificity that shifts with each study’s chosen cutoff value, producing a more honest picture of overall test performance than older univariate approaches.

The headline result was an area under the curve of 0.937 on the HSROC analysis, a figure that places postmortem procalcitonin firmly in the category of clinically excellent diagnostic tests. On the standard scale used in diagnostic medicine, an area under the curve of 0.5 indicates a test no better than a coin flip, while 1.0 represents perfect discrimination. Values above 0.9 are considered outstanding and are rarely achieved by biomarkers in any setting, let alone in the chaotic conditions of the autopsy suite. The researchers also noted that the marker’s performance held up robustly across variable postmortem intervals, meaning the test did not lose its discriminating power simply because a body had been dead for longer before sampling.

Sample choice mattered, however. Most of the included studies relied on peripheral blood, typically drawn from the femoral vein, which has become the standard site for postmortem biochemistry because it is far from the torso and therefore less contaminated by bacteria that translocate from the gut after death. Some studies instead measured procalcitonin in alternative matrices, including pericardial fluid, cerebrospinal fluid, and even the aqueous humour of the eye. Earlier work by the same research groups represented in the analysis, including studies by Palmiere, Schrag, and Schmidt, had explored these fluids as proxies when blood is unavailable or unsuitable, and the new review confirms that peripheral blood remains the preferred and best-validated choice for collection.

The history of this biomarker in forensic medicine stretches back more than two decades. Procalcitonin was first recognized as a marker of severe infection in the early 1990s, when Assicot and colleagues reported high serum concentrations in patients with sepsis in The Lancet. Forensic applications followed quickly: in 2001, Tsokos and Püschel published a landmark study in the International Journal of Legal Medicine demonstrating that serum procalcitonin could serve as a valuable biochemical parameter for the postmortem diagnosis of sepsis. Subsequent studies added C-reactive protein, interleukin-6, tumor necrosis factor alpha, lipopolysaccharide-binding protein, and soluble TREM-1 to the panel of candidate markers, but procalcitonin consistently emerged as one of the strongest single performers. The new meta-analysis is the first to formally synthesize this scattered literature with modern diagnostic accuracy methods.

The authors are careful to acknowledge the limitations of their evidence base. Only eight studies entered the pooled analysis, a small number that limited the statistical power of funnel plot interpretation, the standard tool for detecting publication bias. The included studies also showed heterogeneity in the assays used to measure procalcitonin and in the cutoff values chosen to define a positive result, which is why the researchers call for standardized thresholds in future work. They also emphasize that procalcitonin should never be interpreted in isolation: the biomarker is most powerful when correlated with autopsy findings, histopathology, and postmortem microbiology, forming a triangulated diagnosis rather than a single-molecule verdict.

Even with those caveats, the implications for forensic practice are significant. Sepsis-related deaths are frequently underrecognized, particularly when people die outside hospitals, and misclassification has consequences for mortality statistics, epidemiological surveillance, and legal proceedings ranging from insurance disputes to criminal investigations. A cheap, rapid, and reliable blood test that can be performed on femoral blood during a routine autopsy could transform the diagnostic workup of suspected infection deaths, much as postmortem biochemistry has already improved the detection of diabetic ketoacidosis and electrolyte disturbances. The researchers conclude that procalcitonin is a promising biomarker for forensic diagnostic practice and call for validation across different biological sample types and standardized cutoff values. If those follow-up studies confirm the pooled figures, the humble peptide once known only as a thyroid hormone precursor may become one of the most important tools in the mortuary, giving a voice to the dead about the infection that silenced them.

Subject of Research: Diagnostic accuracy of postmortem blood procalcitonin for identifying sepsis as a cause of death

Article Title: Postmortem Blood Procalcitonin (PCT) for identifying sepsis as a cause of death: a systematic review and meta-analysis

Article References: Chandran, A., Khadanga, S., Gupta, A., Chhabra, D., Kori, A., Lokhande, L., Sangita, M., Agrawal, A., & Arora, A. (2026). Postmortem Blood Procalcitonin (PCT) for identifying sepsis as a cause of death: a systematic review and meta-analysis. International Journal of Legal Medicine. https://doi.org/10.1007/s00414-026-03988-7

Image Credits: AI Generated

DOI: 10.1007/s00414-026-03988-7

Keywords: procalcitonin, sepsis, postmortem diagnosis, forensic pathology, biomarker, meta-analysis, autopsy, diagnostic accuracy, forensic medicine, blood test, International Journal of Legal Medicine, Postmortem

Osteosarcoma is rare, affecting roughly three to four people per million each year, but it is devastating for the young patients it strikes. Treatment typically involves months of chemotherapy to shrink the tumor, followed by surgery to remove it, and then further chemotherapy to mop up any remaining disease. Survival depends heavily on whether the cancer is still localized at diagnosis: patients with localized disease have five-year survival rates of 70 to 77 percent, while those whose tumors have already spread to distant organs fare far worse, with survival dropping to between 24 and 36 percent. Because follow-up care is costly and burdensome, the researchers were interested in whether cheap, routinely collected blood values could help stratify risk without adding financial strain on families.

The research team, led by scientists at VinUniversity and the Vinmec Healthcare System, focused on a cohort of 100 Vietnamese patients with localized osteosarcoma treated between 2022 and 2024. The group was predominantly adolescent, with 72 percent under 18 years old and a mean age at diagnosis of just under 16 years. Notably, 62 percent of the patients were female, a higher proportion than typically reported in osteosarcoma studies, which the authors attribute to the referral patterns of their institution. Nearly all patients received neoadjuvant chemotherapy before surgery, and 90 percent received adjuvant chemotherapy afterward, reflecting standard treatment protocols for this aggressive malignancy.

The central innovation of the study lies in its timing. Most previous biomarker research in osteosarcoma has measured inflammatory blood markers before any treatment begins, capturing the biology of the untreated tumor. This team instead examined blood drawn in the window after neoadjuvant chemotherapy but before the operation, a period the authors describe as an underappreciated stress test of the patient’s body. Chemotherapy profoundly suppresses the bone marrow, and how quickly and completely the immune system rebounds during this interval may reveal something fundamental about a patient’s physiological resilience, their capacity to tolerate treatment, and their ability to keep residual disease in check.

The researchers calculated three ratios from the complete blood counts: the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (LMR). Each ratio pits a different arm of the immune and inflammatory system against another. Lymphocytes are the immune cells responsible for recognizing and killing tumor cells, while monocytes can be recruited by tumors to support their growth and spread. Neutrophils and platelets, meanwhile, are associated with inflammation, angiogenesis, and metastasis. A low LMR, therefore, could signal both weakened antitumor immunity and heightened tumor-promoting inflammation at the same time.

The results were clear for one marker and ambiguous for the rest. Using receiver operating characteristic analysis, the team determined that an LMR cutoff of 1.615 best separated survivors from non-survivors, achieving an area under the curve of 0.72, which was statistically significant. Patients whose LMR was at or above this threshold had significantly better overall survival than those below it. In a multivariable Cox proportional hazards model adjusting for age, sex, and chemotherapy status, an LMR below 1.615 remained an independent predictor of death, carrying a hazard ratio of 4.19. In other words, patients with low post-chemotherapy LMR faced roughly four times the risk of dying compared with those whose immune profiles had recovered more robustly.

Equally interesting was what the LMR did not predict. When the researchers analyzed progression-free survival at 24 months, a window chosen because most osteosarcoma relapses occur within the first two years, none of the biomarkers, including LMR, showed a significant association. This dissociation suggests that the LMR is not simply a proxy for tumor aggressiveness. Instead, the authors argue, it reflects host factors: immune recovery, physiological reserve, and the body’s capacity to withstand the cumulative assault of cytotoxic therapy. Early progression, by contrast, is likely governed by the intrinsic molecular biology of the tumor itself, including its metastatic potential and treatment resistance, which peripheral blood counts cannot capture.

The other markers told a more complicated story. The NLR, which has been reported as a prognostic factor in French, Chinese, and Turkish osteosarcoma cohorts, showed no significant association with survival in this Vietnamese population, in either univariable or multivariable analysis. The PLR was initially associated with poorer survival in univariable analysis, but this signal vanished after adjustment for other variables. Hemoglobin levels also failed to predict outcomes, even though 72 percent of patients were anemic before surgery. In sensitivity analyses treating the biomarkers as continuous variables, LMR retained the direction and approximate magnitude of its protective effect, with each unit increase in LMR associated with a 51 percent reduction in the hazard of death in univariable modeling, and it achieved the highest discriminative accuracy of the three indices, with a C-index of 0.729.

The team also subjected their findings to bootstrap internal validation using 1,000 resamples, an honest accounting of the uncertainty inherent in a small retrospective cohort. After optimism correction, the model’s C-index fell from 0.729 to 0.628, confirming moderate overfitting and modest real-world discrimination. Crucially, however, the bootstrap confidence interval for LMR remained entirely below the null threshold, indicating that its protective association was stable despite the sample size, whereas the interval for PLR crossed 1.0, marking its prognostic value as unreliable in this cohort. The authors also compared their data-derived cutoffs with those from 16 previous studies encompassing 2,762 patients, mostly from China, and found that cutoff values varied enormously across populations, and none of the external thresholds produced statistically significant survival differences in their own cohort.

The study has real limitations that the authors acknowledge candidly. It was retrospective, single-center, and small, with only 10 deaths among 100 patients, which limits statistical power. Missing clinical data on tumor site, size, surgical margins, and histological response prevented more extensive adjustment, even though large registry studies and the intercontinental EURAMOS-1 trial have established these conventional factors as the true pillars of osteosarcoma prognosis. Blood was sampled at only a single time point, and chronic inflammatory conditions, infections, transfusions, and nutritional status were not systematically documented. Still, the core message stands: a simple, nearly free blood ratio, measured at the moment when a young patient’s body is recovering from chemotherapy’s hardest blow, may identify those who need closer surveillance and more intensive support. In resource-limited settings like Vietnam, where the cost of follow-up imaging can determine whether a patient returns to the clinic at all, such an accessible biomarker could make a genuine difference, provided the findings are confirmed in larger, prospective, and more diverse populations.

Subject of Research: Prognostic value of post-chemotherapy blood inflammatory ratios in localized osteosarcoma

Article Title: Lymphocyte-to-monocyte ratio predicts survival in localized osteosarcoma in Vietnamese patients

Article References: Thu Hien, T. T., Quoc, D. N., Thanh, T. D., Thanh Hai, T. T., Quang Sang, N. T., Dung, T. T., Nguyen, X.-H., & Vu, S. H. (2026). Lymphocyte-to-monocyte ratio predicts survival in localized osteosarcoma in Vietnamese patients. iScience, 29(10), Article 117676. https://doi.org/10.1016/j.isci.2026.117676

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117676

Keywords: osteosarcoma, lymphocyte-to-monocyte ratio, biomarker, survival, neoadjuvant chemotherapy, inflammation, immune recovery, Vietnam, pediatric cancer, blood test, prognosis, oncology

The research, led by Jiayu Chen, Xian Xia, and Gang Hu of Nanjing Medical University together with colleagues at Nanjing University of Chinese Medicine and Shanghai Jiao Tong University School of Medicine, takes a deliberately contrarian approach. Rather than pooling all Parkinson’s patients into one diagnostic model, the team first stratified them into molecularly informed subtypes, and only then trained subtype-specific classifiers. The result is striking: within each subtype, multimodal classifiers built on TCR repertoire data achieved an area under the curve (AUC) exceeding 0.8, a level of performance that many considered unattainable for a peripheral blood immune signature in a neurodegenerative disease.

The central insight of the study is that the apparent absence of shared TCR features among Parkinson’s patients likely reflects two intertwined problems: insufficient sample sizes and unaccounted immune heterogeneity within the patient population. T-cell repertoires are enormously diverse. Each person’s body carries millions of distinct TCR clonotypes, generated by stochastic recombination of gene segments and shaped by a lifetime of viral infections, environmental exposures, and immune challenges. Cytomegalovirus alone, which infects a large fraction of adults, imprints durable and highly individual patterns onto the repertoire. When disease-driven TCR signals are weak relative to this background noise, and when patients are grouped together despite having immunologically distinct forms of the disease, any convergent motif shared by a subset of patients is diluted into invisibility.

To solve the stratification problem, the researchers turned to an unusual source of structure: laboratory mice. They reconstructed TCR repertoires from the two largest idiopathic Parkinson’s disease cohorts currently available, drawing on data from the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Disease Biomarkers Program (PDBP), both accessible through the Accelerating Medicines Partnership Parkinson’s Disease knowledge platform. These human datasets were then anchored against three mechanistically distinct mouse models of Parkinson’s disease, including models involving the mitochondrial toxin MPTP and alpha-synuclein pre-formed fibrils, which reproduce different facets of the human pathology. By asking which human patients most resembled which model at the molecular level, the team could sort patients into model-anchored informed subtypes without needing to know in advance what those subtypes were.

This cross-species anchoring strategy is the methodological heart of the paper. Mouse models are often criticized for their imperfect fidelity to human disease, but the authors exploited them in a way that sidesteps that criticism. The models were not used as stand-ins for human Parkinson’s disease; they were used as molecular reference points, each representing a defined mechanism of neurodegeneration. A patient whose blood transcriptome and immune profile aligned with, say, an alpha-synuclein-driven model was assigned to a different subtype than a patient whose profile resembled a toxin-based model. The approach, which the authors describe with tools such as mouse-anchored pathway analysis for disease trajectories, converts a fuzzy clinical category into a set of mechanistically interpretable groups.

Once patients were stratified, the diagnostic modeling became tractable. Within each subtype, the team trained multimodal multiple-instance learning classifiers, a machine learning framework well suited to repertoire data because it can aggregate information across thousands of individual TCR clonotypes without requiring any single clonotype to be present in every patient. This matters because TCR responses to a given antigen are typically public only in part: some sequence motifs recur across individuals, but many are private. Multiple-instance learning lets the classifier learn the collective statistical signature of a disease-reactive repertoire rather than hunting for one magic sequence. Combined with multimodal inputs, the classifiers captured patterns that single-feature approaches would have missed.

The reported performance, with AUC values above 0.8 for both subtypes, is notable in a field where peripheral biomarkers for Parkinson’s disease have struggled to reach clinical utility. Current diagnostic practice relies on motor symptoms, which appear only after substantial loss of dopaminergic neurons in the substantia nigra, and on imaging and cerebrospinal fluid markers that are invasive or expensive. Alpha-synuclein seed amplification assays have recently advanced the field, but a blood-based immune readout would offer a complementary, minimally invasive window into disease biology, potentially usable for screening, monitoring, and patient stratification in clinical trials.

Equally important is the study’s broader lesson about immune-based diagnostics in complex diseases. The authors frame their findings as evidence that disease stratification is a prerequisite, not an afterthought, for TCR repertoire modeling in neurodegeneration. The same logic may explain past failures in other conditions. Immune signatures of chronic obstructive pulmonary disease, cancer, and viral infection have all been shown to depend on how patients are grouped, and the team explicitly drew on previously published COPD and cytomegalovirus TCR datasets to contextualize their Parkinson’s findings. If a disease population contains two or three immunologically distinct subgroups, a single pooled model will fail even when each subgroup carries a perfectly detectable signature. The diagnostic signal does not disappear; it is simply averaged away.

The work also carries implications beyond diagnosis. If model-anchored subtypes correspond to distinct mechanisms of neurodegeneration, they could guide the selection of patients for mechanism-targeted therapies, a persistent challenge in Parkinson’s drug development where candidate drugs may benefit only the subset of patients whose disease follows the matched pathway. The stratification framework, built entirely from peripheral blood data, could in principle be applied at scale to existing cohort studies and biobanks. The authors emphasize that their analysis involved secondary use of de-identified datasets from PPMI, PDBP, and prior studies, with animal work approved by the Institutional Animal Care and Use Committee of Nanjing Medical University.

Caveats remain, as they do for any machine learning study of human immune data. The classifiers were developed within the largest available cohorts, and independent prospective validation will be essential before any clinical deployment. Repertoire data are sensitive to technical factors such as sample handling and sequencing depth, and the authors accounted for quality metrics including RNA integrity in their pipeline. Still, the conceptual advance is clear and likely durable: the immune system does carry readable traces of Parkinson’s disease, but only when researchers first acknowledge that Parkinson’s disease is not one immunological entity. By combining cross-species molecular stratification with modern machine learning, the study transforms a long-standing negative result, the absence of convergent TCR motifs in Parkinson’s patients, into a roadmap for finding them, and offers a template that other fields chasing elusive blood-based biomarkers may soon follow.

Subject of Research: T-cell receptor repertoire-based diagnosis and immune stratification of idiopathic Parkinson's disease

Article Title: Cross-species molecular stratification enables T cell receptor diagnosis of Parkinson’s disease

Article References: Chen, J., Xia, X., Zhang, Y., Tong, X., Liang, Y., Fan, X., Meng, Q., Wei, Y., & Hu, G. (2026). Cross-species molecular stratification enables T cell receptor diagnosis of Parkinson’s disease. Genome Medicine. https://doi.org/10.1186/s13073-026-01776-x

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01776-x

Keywords: Parkinson's disease, T-cell receptor, TCR repertoire, immune stratification, machine learning, biomarkers, neuroimmunology, cross-species analysis, mouse models, alpha-synuclein, blood test, Genome Medicine

The research, led by Mirko Di Rosa and Luca Soraci of IRCCS INRCA in Cosenza, Italy, together with colleagues at the University of Calabria and partner institutions, pooled individual-level data from four prospective European cohorts of older adults. The cohorts were deliberately heterogeneous: 812 community-dwelling older people from the ECHA-PC-MUSA studies, 813 nursing home residents from the SADEL cohort, 579 long-lived individuals and area-matched controls from the Genetics of Healthy Ageing project, and 4,400 hospitalized patients from the REPORTAGE project. In total, 6,604 people were followed for up to five years, and the mean age of the pooled sample was 84.8 years, with a standard deviation of 9.2 years. That breadth of settings is precisely what makes the analysis unusual; most previous studies of RDW and mortality have examined a single clinical population, leaving open the question of whether the marker truly travels across the diverse worlds of home, hospital, and long-term care.

Technically, RDW is reported as a coefficient of variation, the standard deviation of red cell volume divided by the mean corpuscular volume, multiplied by one hundred. It is generated automatically by automated haematology analysers at no additional cost, which is part of its appeal as a potential screening tool. In this study the primary exposure was an RDW-CV of 15 percent or higher, a threshold commonly used to flag anisocytosis, the technical term for increased variability in red cell size. Among the European participants, 41.4 percent met this criterion, and over the five-year follow-up period 69.9 percent of the cohort died, a striking figure that reflects the advanced age and clinical vulnerability of the populations studied.

To test whether elevated RDW was an independent predictor of death rather than a bystander marker of known risk factors, the investigators used multilevel Cox proportional hazards regression, treating the cohort of origin as a random effect. The models adjusted for a formidable battery of geriatric prognostic factors: age, sex, the presence of anaemia, serum albumin, the neutrophil-to-lymphocyte ratio as an index of systemic inflammation, the number of chronic diseases and medications, and impairment in activities of daily living. The models also pre-specified stratification at age 85, allowing the association to be examined separately in the oldest-old, a group in which mortality prediction is notoriously difficult because standard risk factors often lose discriminatory power.

The headline result was unambiguous. Older adults with RDW-CV at or above 15 percent had a 58 percent higher hazard of death during follow-up than those below the threshold, with a pooled adjusted hazard ratio of 1.58 and a 95 percent confidence interval running from 1.48 to 1.68, a finding highly statistically significant at p less than 0.001. Just as important as the magnitude was the consistency: between-cohort heterogeneity, quantified by the theta statistic, was minimal at 0.06, and the direction of the association was concordant in three of the four cohorts. In epidemiological terms, this suggests that the relationship is not an artefact of any single population or care setting but a robust phenomenon that persists whether the blood was drawn in a nursing home, a hospital ward, or a community clinic.

Replication is where many biomarker studies falter, so the team took the additional step of validating their findings externally in an entirely different healthcare system. They analysed 2,471 participants from the 2016 wave of the Health and Retirement Study, a large, nationally representative survey of older Americans. Once again, the elevated-RDW group showed significantly higher mortality, with a hazard ratio whose 95 percent confidence interval extended from 1.23 to 2.19 and a p value below 0.001. The fact that the association survived in a transatlantic sample, with different ancestry profiles, laboratory platforms, and care structures, strengthens the case that RDW captures something fundamental about biological risk rather than a local idiosyncrasy of Italian geriatric medicine.

Why should the variability of red blood cell size carry information about survival? The most widely discussed mechanism implicates chronic, low-grade systemic inflammation and its effects on erythropoiesis, the production of red cells in the bone marrow. Inflammatory cytokines disturb iron metabolism, shorten red cell lifespan, and disrupt the careful regulation of cell volume during maturation, producing a wider distribution of cell sizes. Elevated RDW has also been linked to oxidative stress, nutritional deficiencies, renal dysfunction, and subtle derangements of haematopoietic stem cell dynamics. In this sense, the authors argue, RDW may act as an integrative readout of physiological dysregulation, a single number that summarises the accumulated wear on multiple organ systems. Its independence from the neutrophil-to-lymphocyte ratio and albumin in the adjusted models suggests it is not simply proxying inflammation or malnutrition but adds a distinct dimension of prognostic information.

The association was strongest in the oldest-old, participants aged 85 and above, which is where the clinical implications become most interesting. Predicting mortality in very old patients is a persistent challenge for geriatric medicine; chronological age alone is a blunt instrument, and comprehensive geriatric assessment, while valuable, is time-consuming and requires trained personnel. A marker that costs nothing extra, is already reported on every blood count, and performs at a fixed cut-off across community, nursing home, and hospital populations could help clinicians stratify risk quickly at the bedside. It might, for example, inform decisions about the intensity of investigations, the appropriateness of aggressive interventions, or the prioritisation of patients for closer monitoring. The researchers are careful, however, to frame RDW as a prognostic indicator, not a deterministic verdict; a hazard ratio of 1.58 describes average risk at the population level, and individual outcomes will vary widely.

Several caveats temper the enthusiasm. This is an observational analysis, so elevated RDW identifies association rather than proven causation, and there is as yet no evidence that lowering RDW would change survival. The exposure was measured at a single time point, leaving open questions about the value of tracking RDW trajectories over time, and although the adjustment set was unusually comprehensive for a biomarker study, residual confounding can never be fully excluded. The predominance of Italian cohorts in the pooled European sample also invites replication in other national contexts, even given the American validation. Nonetheless, the study clears a high bar: a fixed, pre-specified threshold, individual-level pooling across markedly different care settings, adjustment for the major geriatric prognostic factors including anaemia, functional status, inflammation, and nutrition, minimal heterogeneity, and external replication in a second continent. Few routinely available laboratory measures can claim a comparable evidentiary pedigree.

The broader lesson may be about where medicine should look for its next generation of risk markers. As automated analysers quietly compute dozens of derived indices with every routine sample, some of the most informative signals may already be sitting in electronic health records, unexamined. Red cell distribution width, a number most patients have never heard of, now has credible evidence behind it as an independent predictor of five-year mortality in older adults across the full spectrum of care, from independent living to intensive hospital treatment. For a rapidly ageing global population, and for clinicians searching for cheap, scalable tools to guide geriatric care, a modest column of digits on a standard blood report may prove to be one of the most consequential numbers in the chart.

Subject of Research: Red cell distribution width as an independent predictor of five-year all-cause mortality in older adults across diverse care settings

Article Title: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation

Article References: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation. (n.d.). https://doi.org/10.1186/s12967-026-08997-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08997-z

Keywords: red cell distribution width, RDW, mortality, aging, geriatrics, complete blood count, oldest old, prognosis, cohort study, anaemia, inflammation, biomarker